EHA 2024 – J&J bows out as Roche looks to confirm
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
The company defends its cancer strategy, and says it's not a me-too developer.
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.